Article Details

Equillium begins phase 3 trial of itolizumab for graft versus host disease | Seeking Alpha

Retrieved on: 2022-03-05 02:05:23

Tags for this article:

Click the tags to see associated articles and topics

Equillium begins phase 3 trial of itolizumab for graft versus host disease | Seeking Alpha. View article details on hiswai:

Excerpt

GVHD is an inflammatory response by the immune system after a bone marrow transplant. The disease can be caused after the immune cells of the ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up